Noncoding RNAs versus Protein Biomarkers in Cardiovascular Disease
Standard
Noncoding RNAs versus Protein Biomarkers in Cardiovascular Disease. / Schulte, Christian; Barwari, Temo; Joshi, Abhishek; Zeller, Tanja; Mayr, Manuel.
in: TRENDS MOL MED, Jahrgang 26, Nr. 6, 06.2020, S. 583-596.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Noncoding RNAs versus Protein Biomarkers in Cardiovascular Disease
AU - Schulte, Christian
AU - Barwari, Temo
AU - Joshi, Abhishek
AU - Zeller, Tanja
AU - Mayr, Manuel
N1 - Copyright © 2020 Elsevier Ltd. All rights reserved.
PY - 2020/6
Y1 - 2020/6
N2 - The development of more sensitive protein biomarker assays results in continuous improvements in detectability, extending the range of clinical applications to the detection of subclinical cardiovascular disease (CVD). However, these efforts have not yet led to improvements in risk assessment compared with existing risk scores. Noncoding RNAs (ncRNAs) have been assessed as biomarkers, and miRNAs have attracted most attention. More recently, other ncRNA classes have been identified, including long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs). Here, we compare emerging ncRNA biomarkers in the cardiovascular field with protein biomarkers for their potential in clinical application, focusing on myocardial injury.
AB - The development of more sensitive protein biomarker assays results in continuous improvements in detectability, extending the range of clinical applications to the detection of subclinical cardiovascular disease (CVD). However, these efforts have not yet led to improvements in risk assessment compared with existing risk scores. Noncoding RNAs (ncRNAs) have been assessed as biomarkers, and miRNAs have attracted most attention. More recently, other ncRNA classes have been identified, including long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs). Here, we compare emerging ncRNA biomarkers in the cardiovascular field with protein biomarkers for their potential in clinical application, focusing on myocardial injury.
KW - Animals
KW - Biomarkers/metabolism
KW - Cardiovascular Diseases/genetics
KW - Humans
KW - MicroRNAs/genetics
KW - Proteins/genetics
KW - RNA, Circular/genetics
KW - RNA, Long Noncoding/genetics
U2 - 10.1016/j.molmed.2020.02.001
DO - 10.1016/j.molmed.2020.02.001
M3 - SCORING: Review article
C2 - 32470385
VL - 26
SP - 583
EP - 596
JO - TRENDS MOL MED
JF - TRENDS MOL MED
SN - 1471-4914
IS - 6
ER -